At Aristea Therapeutics, we aim to expedite the development of treatments for serious inflammatory diseases by harnessing synergistic partnerships and bringing these much-needed therapies to patients as soon as possible.

We are changing the way we treat inflammatory conditions by targeting the immune system, which is at the core of these serious rare diseases.

Aristea is focused on finding paths through the complex immune system to bring real and expedited progress in novel treatment options for people living with serious inflammatory diseases.


Our primary disease under investigation is palmoplantar pustulosis (PPP), a debilitating and painful condition with no approved treatment in the US or EU. This condition is characterized by repeated flares of sterile neutrophil-filled pustules that lead to redness, itching, and burning sensations on the palms of the hands and soles of the feet, which have a major impact on quality of life and the ability to carry out day-to-day activities for those affected.

At Aristea, we have a unique approach; moving upstream of the individual cytokines involved with PPP and targeting CXCR2, which plays an important role in neutrophil recruitment to inflammatory sites. RIST4721, our oral CXCR2 antagonist, is currently in Phase 2b development.

RIST4721 has further potential across a range of neutrophil-mediated diseases; by capitalizing and building upon prior clinical experience with this asset, we can leverage the potential of this immunotherapy to target other serious inflammatory diseases. We are currently developing Phase 2a clinical trials in 4 other diseases – familial Mediterranean fever (FMF), Behcet’s disease,  and hidradenitis suppurativa (HS).